astrazeneca plc-spons adr
(AZN:New York Consolidated)
Transactions by ASTRAZENECA PLC-SPONS ADR (AZN) in the last 6 months
AstraZeneca PLC (LSE:AZN) entered into agreement to acquire respiratory franchise from Almirall, S.A. (CATS:ALM) for $2.1 billion on July 30, 2014. The franchise includes Eklira (aclidinium); LAS40464, LAS100977 (abediterol), LAS191351, LAS194871 and Phase I LAS190792 and multiple pre-clinical programmes. The initial consideration includes payment of $875 million on completion, and up to $1.22 billion in development, launch and sales-related milestones. AstraZeneca has ...
Pfizer Inc. (NYSE:PFE) made a possible offer to acquire AstraZeneca PLC (LSE:AZN) from BlackRock, Inc. (NYSE:BLK) and others for £62.7 billion on April 26, 2014. Pfizer is considering a possible transaction, to be paid in a combination of cash and shares in the combined entity. Pfizer Inc. will pay £15.9 per share as cash and 1.845 stocks per share of AstraZeneca PLC. The transaction, if consummated, is expected to result in the combination of the two companies under ...
Pfizer Inc. (NYSE:PFE) made a preliminary and conditional proposal to acquire AstraZeneca PLC (LSE:AZN) for £58 billion in cash and stock on January 5, 2014. Under the terms, Pfizer would pay £13.98 in cash and issue 1.758 Pfizer shares for each share of AstraZeneca. The combined company will be listed and headquartered in United States.
Fares Noujaim, Adrian Mee, Michael Findlay and Geoff Iles of Merrill Lynch, Pierce, Fenner & Smith Inc and Merrill Lynch International ...
AstraZeneca plc (LSE:AZN) announces a share repurchase program. Under the program, the company will repurchase up to 126,096,700 shares, representing 10% of its issued capital. The minimum price (exclusive of expenses) which may be paid for each ordinary share is $0.25. The maximum price (exclusive of expenses) which may be paid for each ordinary share is the higher of either an amount equal to 105% of the average of the middle market quotations for an ordinary share ...
Manchester Science Park Ltd. agreed to acquire Alderley Park site in Cheshire from AstraZeneca PLC (LSE:AZN) on March 11, 2014. The transaction is expected to close by the end of March 2014. Funding for the deal was provided by Bruntwood, MSP and Cheshire East Council, with Bruntwood as the majority funder. JLL acted as real estate advisor to AstraZeneca in the transaction. Michael Birchall and Stephen Kinsey of Addleshaw Goddard Ltd. acted as legal advisor to Manchester ...
|No competitor information is available for AZN.|
|View Industry Companies|
|No financial data is available for AZN.|